American Journal of Cancer Prevention
ISSN (Print): 2328-7314 ISSN (Online): 2328-7322 Website: http://www.sciepub.com/journal/ajcp Editor-in-chief: Nabil Abdel-Hamid
Open Access
Journal Browser
Go
American Journal of Cancer Prevention. 2020, 8(1), 1-6
DOI: 10.12691/ajcp-8-1-1
Open AccessArticle

Hematological and Biochemical Changes in Patients with Multiple Myeloma Treated with Bortezomib Based Triple Drug Combination Chemotherapy

Mahbuba Sharmin1, , Amin Lutful Kabir2, Naseeb Muhammad. Irshadullah3, Mohammad Shahidul Alam4, 5, A S M Anwarul Kabir6, Abdul Aziz2 and Hafizur Rahman7

1Department of Hematology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka

2Hematology Department, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka

3Shaheed Tajuddin Ahmad Medical College, Gazipur

4Department of Botany, Rajshahi University

5Department of Physical Education and Sports Sciences, Rajshahi University

6Holy Family Red Crescent Medical College and Hospital, Dhaka

7Hematology and Cancer Biology, Clinical Laboratories, Laboratory Sciences and Services Division, ICDDRB, Dhaka

Pub. Date: July 02, 2020

Cite this paper:
Mahbuba Sharmin, Amin Lutful Kabir, Naseeb Muhammad. Irshadullah, Mohammad Shahidul Alam, A S M Anwarul Kabir, Abdul Aziz and Hafizur Rahman. Hematological and Biochemical Changes in Patients with Multiple Myeloma Treated with Bortezomib Based Triple Drug Combination Chemotherapy. American Journal of Cancer Prevention. 2020; 8(1):1-6. doi: 10.12691/ajcp-8-1-1

Abstract

Background: Multiple Myeloma (MM) is a neoplastic clonal disorder and accounts for 1% of malignant tumors and 10%–15% of hematopoietic neoplasms. The prognosis of Multiple Myeloma has reversed by the advent of novel agents and triple combination therapy (Bortezomib, Thalidomide, Dexamethasone) that serve the basis of future strands of care in Multiple Myeloma patients. Objective: The aim of the study was to assess the safety, efficacy and tolerability of Bortezomib in newly diagnosed cases of Multiple Myeloma patients in Bangladesh. Materials &Methods: We undertook this clinicopathological study to assess the profile of Multiple Myeloma patients, evaluate hematological and biochemical response of 36 newly diagnosed cases of MM with or without renal impairment receiving 4 cycles of Bortezomib, Thalidomide and Dexamethasone (BTD). Results: Among the study population, 36(100%) patients had weakness. followed by anaemia (97%), bone pain (89%) and renal impairment (44%). During treatment, 8 patients (22%) suffered from somnolence, 5 patients (14%) had Peripheral neuropathy and 6 (17%) patients complained of constipation. We found 8% suffered from hyperglycaemia, 3% rash, 3% cardiac arrest, 6% electrolyte imbalance and life threatening intracranial haemorrhage occurred in 1 patient (3%). Out of 36 patients, complete response achieved in 18 patients (50%), where 6 patients (16%) showed partial response, 10 (28%) showed very good partial response and 2 (6%) patients showed no response. The overall response rate was 94% belonged to complete response(CR), Partial response(PR),very good partial response(VGPR). Conclusion: Bortezomib based combination therapy is a highly effective and safe regimen for newly diagnosed Multiple Myeloma patients. . It can be administered safely in the outpatient setting provided by clinicians.

Keywords:
multiple myeloma BTD M protein

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  A V Hoffbrand, Danial Catovsky, Edward G.D, Tuddenham: Post graduate haematology, 7thed, UK Blackwell Publishing Limited, 2016, 577-598.
 
[2]  A V Hoffbrand Danial Catovsky, Edward G.D, Tuddenham: Post graduate haematology, 6thed, UK Blackwell Publishing Limited, 2011, 681-701.
 
[3]  AV Hoffbrand, PAH Moss, JE Pettit: Essential haematology 5thed,UK, Black well publishing company, 2006, 216-228.
 
[4]  Angela Dispenzieri, Martha Q lacy and Philip R. Gripp, Multiple Myeloma, Edited by John Grcer: Wintrobes clinical Haematology, Philadelphia, Lippincott, Williams and Wilkins, 2004, 2584-88.
 
[5]  BarlogieB,Epstein J, Selvanauagam P, Alexanian R, Plasma cell myeloma-new biological insights and advances in therapy, blood, 73: 865-879. 1989
 
[6]  Jagannath, BGM Durie, J Wolf. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology. 129(6): 776-783, june 2005.
 
[7]  Antonia Field-Smith, Gareth J Morgan and Faith E Davies. Bortezomib (Velcade™) in the treatment of Multiple Myeloma. 2(3): 271-279; September, 2006.
 
[8]  Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 114(15): 3139-3146; 2009..
 
[9]  Kyle RA, Leong T, Li S, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem celltransplantation. Center. 106(9): 1958- 1966; 2006.
 
[10]  van de Velde H, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 92(10): 1399-1406; 2007.
 
[11]  Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System(ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 23(6): 1152-1157; 2009.
 
[12]  Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the im-pact of novel therapies. Blood. 111(5): 2516-2520. 2008.
 
[13]  Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 23(3): 449-456; 2009.
 
[14]  San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisolone for initial treatment of multiple myeloma. NEngl J Med. 359(9): 906-917. 2008.
 
[15]  Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. NEngl J Med; 352(24): 2487-2498. 2005.
 
[16]  Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. NEngl J Med. 57(21): 2123-2132. 2007.
 
[17]  Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiplemyeloma in North America. NEngl J Med. 357(21): 2133-2142; 2007.
 
[18]  Hideshima T, Richardson P, Chauhan D, et al.The proteasome inhibitor PS-341 inhibits growth,induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.CancerRes. 61(7): 3071-3076. 2001.
 
[19]  Harousseau J-L, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 91(11): 1498-1505. 2006.
 
[20]  Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial.J ClinOncol; 26(suppl): 455s. Abstract 8505. 2008.
 
[21]  Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol; 27(34):5713-5719.2009.
 
[22]  Anderson KC, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study. J Clin Oncol; 27(suppl):442s. Abstract 8536; 2009..
 
[23]  Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol; 144(6): 895-903. 2009.
 
[24]  Richardson PG, Xie W, Mitsiades C, et al. Single agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 27(21): 3518-3525. 2009.
 
[25]  Tribikram Panda, Sidhartha Das, Rabindra Kumar Jena, Bidyut Prava Das, Sashi Bhusan Rout.Hematological, Biochemical and Renal Changes in Patients of Multiple Myeloma Treated with Bortezomib Based Triple Drug Chemotherapy. Journal of The Association of Physicians of India Vol. 67 July 2019.
 
[26]  Pegu AK, Dutta A, Todi VK. Clinical profile of multiple myeloma in a tertiary care center from North East India. J. Evolution Med. Dent. Sci.5(52):3382-3385. 2016.
 
[27]  Arundhati G. Diwan, Sushil A. Gandhi1, Kavita Krishna, Vineet P. ShindeClinical profile of the spectrum of multiple myeloma in a teaching hospital. Medical Journal of Dr. D.Y. Patil University | | Vol 7 | Issue 2/March-April, 2014.
 
[28]  Arundhati G. Diwan, Sushil A. Gandhi1, Kavita Krishna, Vineet P. Shinde.Clinical profile of the spectrum of multiple myeloma in a teaching hospital. ,IP: 45.248.151.151]April, 18; 2020.